An interventional study of Transthoracic echocardiography and 24-hour ECG Monitor in Atrial Fibrillation and Atrial Fibrillation, Persistent, sponsored by Saint Petersburg State University, Russia. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.
Sponsored by Saint Petersburg State University, Russia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Atrial Fibrillation with a site in Russian Federation — 4 open to participants now, 5 under way, none of them phase 3. Atrial Fibrillation · Russian Federation.
Among the 107 studies in Atrial Fibrillation with a site in Russian Federation, this one is the 49th largest by planned enrollment of the 80 interventional ones that give a count, is the only one that started in 2024, is one of 18 with no phase, and was the 106th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →4 of the 107 studies in Atrial Fibrillation with a site in Russian Federation are open now. Recruiting first, the newest first:
Vasily I. Kaleda · Sites in Russian Federation
Ages 18+
Meshalkin Research Institute of Pathology of Circulation · Sites in Russian Federation
Ages 18–80
Center for Strategic Planning, of the Federal Medical and Biological Agency · Sites in Russian Federation
Ages 18+
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 26 · Phase 3 28 · Phase 4 10
First in 2001; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 175 across the 80 interventional studies, 1,063 across the 26 observational. Of the 80 that completed or were terminated, 27 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 107 have an industry lead sponsor. The 10 most frequent:
Saint Petersburg State University, Russia is the lead sponsor of 34 studies on the registry; 14 are open to participants now.
Saint Petersburg State University, Russia has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
2 of the studies in Atrial Fibrillation with a site in Russian Federation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05920226Ryazan State Medical UniversityMyocardial Fibrosis in Patients With Permanent Pacemakers | 2027-07-01 |
| NCT06823778Vasily I. KaledaProphylactic Radiofrequency Left Atrial Posterior Wall Isolation to Prevent Atrial Fibrillation After Cardiac Surgery | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 107 studies in Atrial Fibrillation with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate benefits of electric cardioversion in the early and long-term postoperative period in patients after radiofrequency catheter isolation of pulmonary veins. Parameters of the left atrium will be evaluated by transthoracic echocardiography and electroanatomic mapping. Preservation of the sinus rhythm will be assessed by 24-hour electrocardiographic monitoring.
The main question that is planned to be answered is:
Does a reverse remodeling of the left atrium and/or a decrease in the progression of the fibrosis zone occur after performing electrical cardioversion (and before subsequent catheter ablation) in patients with persistent and long-standing persistent atrial fibrillation (AF)? Can performed electrical cardioversion serve as a predictor of AF freedom in this group of patients?
Participants will undergo a follow-up examinations (echocardiography, ECG, 24-hour ECG monitoring) at the 3rd, 6th and 12th months after catheter ablation. Based on the results of these examinations, the recurrence rate of AF will be estimated.
Two groups of patients will include both persistent and long-standing persistent AF. Experimental group will include patients who underwent electrical cardioversion before the intervention, and active comparator group will include those patients who did not undergo it. The experimental group will be subdivided into a persistent AF patients who were successfully cardioverted in sinus rhythm and persistent AF patients who failed to restore sinus rhythm during DC at the time of catheter ablation. Analysis and comparison of subgroups will be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Depending on the duration of atrial fibrillation and anatomic parameters of the left atrium (according to heart ultrasound), patients will undergo electric cardioversion before the primary radiofrequency catether pulmonary veins' isolation. The experimental group will be subdivided into a persistent AF patients who were successfully cardioverted in sinus rhythm and persistent AF patients who failed to restore sinus rhythm during DC at the time of catheter ablation.
Diagnostic Test: Transthoracic echocardiography · Diagnostic Test: 24-hour ECG Monitor · Procedure: Electroanatomic mapping
Primary interventional treatment is performed without restoration of the sinus rhythm.
Diagnostic Test: Transthoracic echocardiography · Diagnostic Test: 24-hour ECG Monitor · Procedure: Electroanatomic mapping
Standard assessment of the parameters of the left atrium: size, volume, volume indices
Assessment of cardiac arrhythmias according to 24-hour monitoring data
Intraoperative assessment of low voltage areas (potential fibrosis zones)
Freedom from atrial fibrillation 6 months after catheter ablation
Absence of events of sustained atrial tachycardia according to 24-hour ECG monitoring
Time frame: Echocardiographic assessment of the parameters of the left atrium and 24-hour ECG monitoring is performed at the time of admission to the hospital; after 3,6 and 12 months after intervention or the latest data in the event of death, whenever comes first
Reverse remodeling of the left atrium and improvement of the contractility of the left ventricle
An increase in the LV ejection fraction, a decrease in the volume and size of the left atrium according to transthoracic echocardiography
Time frame: Echocardiographic assessment of the parameters of the left atrium and 24-hour ECG monitoring is performed at the time of admission to the hospital; after 3,6 and 12 months after intervention or the latest data in the event of death, whenever comes first
Freedom from atrial fibrillation 12 months after catheter ablation
Absence of events of sustained atrial tachycardia according to 24-hour monitoring
Time frame: Echocardiographic assessment of the parameters of the left atrium and 24-hour ECG monitoring is performed at the time of admission to the hospital; after 3,6 and 12 months after intervention or the latest data in the event of death, whenever comes first
Improving the quality of life of patients with atrial fibrillation
Assessment of the quality of life of patients with atrial fibrillation based on a questionnaire: Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Questionnaire - provides an overall score; plus scores for symptoms, daily activities, treatment concerns, and treatment satisfaction. Overall or subscale scores range from 0-100. A score of 0 corresponds to complete disability (or responding "extremely" limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability (or responding "not at all" limited, difficult or bothersome to all questions answered).
Time frame: Patients fill out questionnaires upon admission to the hospital; 3, 6 and 12 months after surgical treatment or the latest data in the event of death, whenever comes first
Plan to share: No — Individual participant data is not planned to be shared with other parties
Started Nov 2024 (actual). Primary completion is estimated for Sep 2025, 10 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 10 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saint Petersburg State University, Russia